NEW YORK (GenomeWeb News) – Clinical Data today said that it has started a collaboration with the University of Pittsburgh to discover and validate genetic variants that could predict response to certain cancer treatments.

The partners will focus on variants in the Fc gamma receptor genes, which they believe could potentially predict patient response to monoclonal antibody therapies, such as cetuximab (Erbitux) and trastuzumab (Herceptin), and other monoclonal antibodies of the IgG1 subclass for treating cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.